F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins - PubMed (original) (raw)
doi: 10.1038/nm836. Epub 2003 Mar 3.
Fredric Van Goor, Stefano Luccioli, Eric M Billings, Alexander O Vortmeyer, Lajos Baranyi, Janos Szebeni, Carl R Alving, Michael C Carroll, Ira Berkower, Stanko S Stojilkovic, Dean D Metcalfe
Affiliations
- PMID: 12612546
- DOI: 10.1038/nm836
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
Milan Basta et al. Nat Med. 2003 Apr.
Abstract
High-dose intravenous immunoglobulin (IVIG) prevents immune damage by scavenging complement fragments C3b and C4b. We tested the hypothesis that exogenous immunoglobulin molecules also bind anaphylatoxins C3a and C5a, thereby neutralizing their pro-inflammatory effects. Single-cell calcium measurements in HMC-1 human mast cells showed that a rise in intracellular calcium caused by C3a and C5a was inhibited in a concentration-dependent manner by IVIG, F(ab)2-IVIG and irrelevant human monoclonal antibody. C3a- and C5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basophils were also suppressed by exogenous immunoglobulins. In a mouse model of asthma, immunoglobulin treatment reduced cellular migration to the lung. Lethal C5a-mediated circulatory collapse in pigs was prevented by pretreatment with F(ab)2-IVIG. Molecular modeling, surface plasmon resonance (SPR) and western blot analyses suggested a physical association between anaphylatoxins and the constant region of F(ab)2. This binding could interfere with the role of C3a and C5a in inflammation.
Similar articles
- Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition.
Basta M. Basta M. Mol Immunol. 2008 Oct;45(16):4073-9. doi: 10.1016/j.molimm.2008.07.012. Epub 2008 Aug 15. Mol Immunol. 2008. PMID: 18706699 Review. - Expression of high- and low-affinity receptors for C3a on the human mast cell line, HMC-1.
Legler DF, Loetscher M, Jones SA, Dahinden CA, Arock M, Moser B. Legler DF, et al. Eur J Immunol. 1996 Apr;26(4):753-8. doi: 10.1002/eji.1830260405. Eur J Immunol. 1996. PMID: 8625964 - Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.
el-Lati SG, Dahinden CA, Church MK. el-Lati SG, et al. J Invest Dermatol. 1994 May;102(5):803-6. doi: 10.1111/1523-1747.ep12378589. J Invest Dermatol. 1994. PMID: 7513741 - Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
Takabayashi T, Shimizu S, Clark BD, Beinborn M, Burke JF, Gelfand JA. Takabayashi T, et al. Surgery. 2004 May;135(5):544-54. doi: 10.1016/j.surg.2003.09.010. Surgery. 2004. PMID: 15118592 - The role of the complement anaphylatoxins in the recruitment of eosinophils.
DiScipio RG, Schraufstatter IU. DiScipio RG, et al. Int Immunopharmacol. 2007 Dec 20;7(14):1909-23. doi: 10.1016/j.intimp.2007.07.006. Epub 2007 Aug 6. Int Immunopharmacol. 2007. PMID: 18039528 Review.
Cited by
- Mechanisms of long COVID and the path toward therapeutics.
Peluso MJ, Deeks SG. Peluso MJ, et al. Cell. 2024 Oct 3;187(20):5500-5529. doi: 10.1016/j.cell.2024.07.054. Epub 2024 Sep 25. Cell. 2024. PMID: 39326415 Review. - Complement Component C5a and Fungal Pathogen Induce Diverse Responses through Crosstalk between Transient Receptor Potential Channel (TRPs) Subtypes in Human Conjunctival Epithelial Cells.
Rech L, Dietrich-Ntoukas T, Reinach PS, Brockmann T, Pleyer U, Mergler S. Rech L, et al. Cells. 2024 Aug 9;13(16):1329. doi: 10.3390/cells13161329. Cells. 2024. PMID: 39195219 Free PMC article. - Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.
Neth O, Mahlaoui N, Cunningham-Rundles C. Neth O, et al. Clin Exp Immunol. 2024 Oct 16;218(2):136-150. doi: 10.1093/cei/uxae059. Clin Exp Immunol. 2024. PMID: 39011978 Review. - Multifaceted Tissue-Protective Functions of Polyvalent Immunoglobulin Preparations in Severe Infections-Interactions with Neutrophils, Complement, and Coagulation Pathways.
Schmidt C, Weißmüller S, Heinz CC. Schmidt C, et al. Biomedicines. 2023 Nov 10;11(11):3022. doi: 10.3390/biomedicines11113022. Biomedicines. 2023. PMID: 38002022 Free PMC article. Review. - What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.
Aboul-Fotouh S, Mahmoud AN, Elnahas EM, Habib MZ, Abdelraouf SM. Aboul-Fotouh S, et al. Virol J. 2023 Oct 24;20(1):241. doi: 10.1186/s12985-023-02210-z. Virol J. 2023. PMID: 37875904 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous